Short answer
Axsome Therapeutics, Inc. (AXSM) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results and operational update announced for the three months ended March 31, 2026.
Axsome Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results and operational update announced for the three months ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operating details
Item 8.01 · Other Events
- Updated corporate presentation posted May 4, 2026, signaling refreshed investor messaging
- Exhibit 99.2 contains the substantive presentation, including any pipeline, clinical, or commercial updates
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net product revenue $191.2M, up 57% YoY, led by AUVELITY sales of $153.2M, up 59%
- AUVELITY Alzheimer’s agitation approval expands its addressable market, with commercial launch targeted for June 2026
- Net loss widened to $64.5M from $59.4M as SG&A increased to $185.0M for launches and direct-to-consumer advertising
- Cash declined to $305.1M from $322.9M, while management expects funding through cash-flow positivity
- NDA submitted for AXS-12 cataplexy treatment; pipeline added AXS-20 for schizophrenia and Tourette syndrome
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axsome Therapeutics, Inc. 8-K filings
Get the next AXSM 8-K as it lands
Follow AXSM for push alerts, or ask the research agent what this filing means.